Early detection of antiseizure medication inefficacy using an implantable continuous EEG system and a personalized model: a case study

Evaluating anti-seizure medication (ASM) efficacy can be limited by inaccurate seizure diaries and periodic fluctuations in seizure frequency, known as seizure cycles. These limitations may prolong monitoring of ineffective treatments. This study explores implantable continuous EEG monitoring (iCEM™) with Epiminder's Minder® system and timeseries modelling to improve efficacy assessments. This retrospective case study examines a 49-year-old female with drug-resistant focal epilepsy with iCEM (Nov. 2019). The participant maintained a seizure diary and was followed-up for 3 years. ASMs were changed in Aug.-Oct. 2020. A personalised autoregressive model incorporating interictal epileptiform discharge cycles to project 3-monthly seizure rates was trained and validated on post-drug data then tested on four held-out datasets (two pre-drug and two post-drug). The Kruskal-Wallis test assessed model performance between drug periods (α = 0.05). Only 37 % of seizures were reported. Post-drug, diary-reported seizures increased while detected seizures decreased, but both remained within normal seizure rate variability. ASM inefficacy was addressed after 3 years. The autoregressive model mean squared error post-drug was 0.17 and 0.13 seizures per day over 3-months<sup>2</sup>, which were significantly different from pre-drug (0.49 and 0.58 seizures per day over 3-months<sup>2</sup>, <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>H</mml:mi></mml:math> =336.82, p = 2.44exp.<sup>-89</sup>), suggesting the model could recognise when an altered drug regimen affected seizure rate and interictal epileptiform discharges. Seizures identified using iCEM combined with an individualised model may be able to distinguish drug-induced changes in seizure rate from normal variability. This proof-of-concept study offers useful information towards the development of methods that can support early treatment assessments, potentially shortening the time to find an optimal therapy.

Authors

Institutions

Publication Details

Journal
Epilepsy & Behavior Reports
Published
2025-09-24
DOI
https://doi.org/10.1016/j.ebr.2025.100829
Primary Topic
EEG and Brain-Computer Interfaces
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Early detection of antiseizure medication inefficacy using an implantable continuous EEG system and a personalized model: a case study

David B. Grayden, Andrew R. Peterson, Mark Cook, Alan Lai et al.
Epilepsy & Behavior Reports
EEG and Brain-Computer Interfaces
article

Early detection of antiseizure medication inefficacy using an implantable continuous EEG system and a personalized model: a case study

David B. Grayden, Andrew R. Peterson, Mark Cook, Alan Lai, Ashley Reynolds
article en

Abstract

Evaluating anti-seizure medication (ASM) efficacy can be limited by inaccurate seizure diaries and periodic fluctuations in seizure frequency, known as seizure cycles. These limitations may prolong monitoring of ineffective treatments. This study explores implantable continuous EEG monitoring (iCEM™) with Epiminder's Minder® system and timeseries modelling to improve efficacy assessments. This retrospective case study examines a 49-year-old female with drug-resistant focal epilepsy with iCEM (Nov. 2019). The participant maintained a seizure diary and was followed-up for 3 years. ASMs were changed in Aug.-Oct. 2020. A personalised autoregressive model incorporating interictal epileptiform discharge cycles to project 3-monthly seizure rates was trained and validated on post-drug data then tested on four held-out datasets (two pre-drug and two post-drug). The Kruskal-Wallis test assessed model performance between drug periods (α = 0.05). Only 37 % of seizures were reported. Post-drug, diary-reported seizures increased while detected seizures decreased, but both remained within normal seizure rate variability. ASM inefficacy was addressed after 3 years. The autoregressive model mean squared error post-drug was 0.17 and 0.13 seizures per day over 3-months<sup>2</sup>, which were significantly different from pre-drug (0.49 and 0.58 seizures per day over 3-months<sup>2</sup>, <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>H</mml:mi></mml:math> =336.82, p = 2.44exp.<sup>-89</sup>), suggesting the model could recognise when an altered drug regimen affected seizure rate and interictal epileptiform discharges. Seizures identified using iCEM combined with an individualised model may be able to distinguish drug-induced changes in seizure rate from normal variability. This proof-of-concept study offers useful information towards the development of methods that can support early treatment assessments, potentially shortening the time to find an optimal therapy.

Epilepsy & Behavior ReportsVol. 32
The University of Melbourne (AU), St Vincent's Hospital Melbourne (AU), Mind Australia (AU)
Openalex Percentile: Top 74%
EEG and Brain-Computer Interfaces
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.